دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Docetaxel Versus Best Supportive Care in Non-Small-Cell Lung Cancer and Pemetrexed Versus Docetaxel in Second-Line Non-Small-Cell Lung Cancer.
Stinchcombe, Thomas E. MD 1,2,,
doi : 10.1200/JCO.22.02871
Volume 41(15) pgs. 2671-2866,e42-e62 May 20, 2023
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy.
Shepherd, Frances A.; Dancey, Janet; Ramlau, Rodryg; Mattson, Karin; Gralla, Richard; O'Rourke, Mark; Levitan, Nathan; Gressot, Laurent; Vincent, Mark; Burkes, Ronald; Coughlin, Susan; Kim, Yong; Berille, Jocelyne
doi : 10.1200/JCO.22.02545
To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum-based chemotherapy
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
Hanna, Nasser; Shepherd, Frances A.; Fossella, Frank V.; Pereira, Jose R.; De Marinis, Filippo; von Pawel, Joachim; Gatzemeier, Ulrich; Tsao, Thomas Chang Yao; Pless, Miklos; Muller, Thomas; Lim, Hong-Liang; Desch, Christopher; Szondy, Klara; Gervais, Radj; Shaharyar,; Manegold, Christian; Paul, Sofia; Paoletti, Paolo; Einhorn, Lawrence; Bunn, Paul A. Jr.
doi : 10.1200/JCO.22.02546
To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy.
Combination Immune Checkpoint Inhibition: Is First Line Best?.
McArthur, Grant A. MBBS, PhD 1,2,,
doi : 10.1200/JCO.23.00061
Combination Immune Checkpoint Inhibition: Is First Line Best?.
Dorff, Tanya MD 1,,; Tripathi, Abhishek MD 1,
doi : 10.1200/JCO.23.00061
Implementing Evidence-Based Tobacco Treatment Interventions in Oncology to Achieve Optimal Outcomes.
Studts, Jamie L. PhD 1,2,,; Hamann, Heidi A. PhD 3,4
doi : 10.1200/JCO.22.02534
DPYD Testing: Time to Put Patient Safety First.
Baker, Sharyn D. PharmD, PhD 1,; Bates, Susan E. MD 2,; Brooks, Gabriel A. MD 3,; Dahut, William L. MD 4,; Diasio, Robert B. MD 5; El-Deiry, Wafik S. MD, PhD 6,; Evans, William E. PharmD 7,; Figg, William D. PharmD, MBA 8,; Hertz, Dan L. PharmD, PhD 9,; Hicks, J. Kevin PharmD, PhD 10,; Kamath, Suneel MD 11,; Kasi, Pashtoon Murtaza MD 12,; Knepper, Todd C. PharmD 10,; McLeod, Howard L. PharmD 13,; O'Donnell, Peter H. MD 14,; Relling, Mary V. PharmD 7,; Rudek, Michelle A. PharmD, PhD 15,; Sissung, Tristan M. PhD 8; Smith, D. Max PharmD 16,; Sparreboom, Alex PhD 1; Swain, Sandra M. MD 16,; Walko, Christine M. PharmD 10,
doi : 10.1200/JCO.22.02364
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.
Merino, Margret MD 1,,; Kasamon, Yvette MD 1; Theoret, Marc MD 1,2; Pazdur, Richard MD 1,2; Kluetz, Paul MD 1,2; Gormley, Nicole MD 1
doi : 10.1200/JCO.23.00225
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?.
Tannock, Ian F. MD, PhD 1,2,,; Goldstein, Daniel A. MD 2,3,4,5,; Ofer, Jonathan MD 3; Gyawali, Bishal MD 6,; Meirson, Tomer MD 3,
doi : 10.1200/JCO.23.00280
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Davies, Andrew J. PhD 1,; Barrans, Sharon PhD 2; Stanton, Louise MSc 3; Caddy, Josh BSc 3; Wilding, Sam MSc 3; Saunders, Geoff BSc 3; Mamot, Christoph MD 4; Novak, Urban MD 5,; McMillan, Andrew MD 6,; Fields, Paul MD 7; Collins, Graham P. MD 8,; Stephens, Richard MA 9; Cucco, Francesco PhD 10; Sha, Chulin PhD 11; van Hoppe, Moniek PhD 2,; Tooze, Reuben PhD 12,; Davies, John R. PhD 11; Griffiths, Gareth PhD 3,; Schuh, Anna MD 13,; Burton, Catherine MD 2,; Westhead, David R. PhD 11; Du, Ming-Qing PhD 10,; Johnson, Peter W.M. MD 1,
doi : 10.1200/JCO.23.00033
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto, Paolo Antonio MD 1,,; Lipson, Evan J. MD 2,; Dummer, Reinhard MD 3,; Larkin, James PhD 4,; Long, Georgina V. PhD 5,; Sanborn, Rachel E. MD 6,; Chiarion-Sileni, Vanna MD 7,; Dreno, Brigitte MD, PhD 8; Dalle, Stephane MD, PhD 9; Schadendorf, Dirk MD 10,; Callahan, Margaret K. MD, PhD 11,; Nyakas, Marta MD 12,; Atkinson, Victoria MD 13,; Gomez-Roca, Carlos Alberto MD 14,; Yamazaki, Naoya MD, PhD 15,; Tawbi, Hussein A. MD 16,; Sarkis, Naomey PharmD, RPh 17,; Warad, Deepti MD 17,; Dolfi, Sonia PhD 18,; Mitra, Priyam PhD 19; Suryawanshi, Satyendra PhD 20,; Grob, Jean-Jacques MD, PhD 21,
doi : 10.1200/JCO.22.02072
Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation.
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer.
Halabi, Susan PhD 1,2,,; Yang, Qian PhD 1; Roy, Akash PhD 1; Luo, Bin PhD 1; Araujo, John C. MD 3; Logothetis, Christopher MD 3,; Sternberg, Cora N. MD 4,; Armstrong, Andrew J. MD 2,; Carducci, Michael A. MD 5,; Chi, Kim N. MD 6,; de Bono, Johann S. MD 7,; Petrylak, Daniel P. MD 8,; Fizazi, Karim MD 9,; Higano, Celestia S. MD 10,; Morris, Michael J. MD 11,; Rathkopf, Dana E. MD 11,; Saad, Fred MD 12,; Ryan, Charles J. MD 13,; Small, Eric J. MD 14,; Kelly, William Kevin DO 15,
doi : 10.1200/JCO.22.02661
We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naive mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model.
Smoking Cessation After Diagnosis of Kidney Cancer Is Associated With Reduced Risk of Mortality and Cancer Progression: A Prospective Cohort Study.
Sheikh, Mahdi MD, PhD 1,; Mukeriya, Anush MD 2; Zahed, Hana MSc 1; Feng, Xiaoshuang PhD 1; Robbins, Hilary A. PhD 1; Shangina, Oxana PhD 2; Matveev, Vsevolod MD 3,; Brennan, Paul PhD 1; Zaridze, David MD, PhD 2
doi : 10.1200/JCO.22.02472
To investigate whether postdiagnosis smoking cessation may affect the risk of death and disease progression in patients with renal cell carcinoma (RCC) who smoked at the time of diagnosis. METHODS: Two hundred twelve patients with primary RCC were recruited between 2007 and 2016 from the Urological Department in N.N
Integrating Tobacco Treatment Into Oncology Care: Reach and Effectiveness of Evidence-Based Tobacco Treatment Across National Cancer Institute-Designated Cancer Centers.
Hohl, Sarah D. PhD, MPH 1,2,; Matulewicz, Richard S. MD, MSCI 3; Salloum, Ramzi G. PhD 4; Ostroff, Jamie S. PhD 5,; Baker, Timothy B. PhD 6; Schnoll, Robert PhD 7; Warren, Graham MD, PhD 8,; Bernstein, Steven L. MD 9; Minion, Mara MA 1; Lenhoff, Katie MPH 10; Dahl, Neely MPH 11; Juon, Hee Soon MSN, PhD 12; Tsosie, Ursula MS 13; Fleisher, Linda PhD, MPH 14,; D'Angelo, Heather PhD 1; Ramsey, Alex T. PhD 15,16; Ashing, Kimlin T. PhD 17,; Rolland, Betsy PhD, MPH, MLIS 1,18; Nolan, Margaret B. MD, MS 1,19; Bird, Jennifer E. PhD 1; Nguyen, Claire V.T. BA 1; Pauk, Danielle BA 1; Adsit, Robert T. MEd 1,20; Tindle, Hilary A. MD, MPH 20,21,; Shoenbill, Kimberly MD, PhD 22; Yeung, Sophia MHA, CTTS 23; Presant, Cary A. MD 24,; Wiseman, Kara P. MPH, PhD 25; Wen, Kuang-Yi PhD 12,; Chichester, Lou-Anne MPH 5; Chen, Li-Shiun MD, MPH, ScD 15,16
doi : 10.1200/JCO.22.00936
Quitting smoking improves patients' clinical outcomes, yet smoking is not commonly addressed as part of cancer care. The Cancer Center Cessation Initiative (C3I) supports National Cancer Institute-designated cancer centers to integrate tobacco treatment programs (TTPs) into routine cancer care.
Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
Kinney, Anita Y. PhD, RN 1,2,; Walters, Scott T. PhD 3; Lin, Yong PhD 1; Lu, Shou-En PhD 1; Kim, Arreum MBS, MS 2; Ani, Julianne MPH 2; Heidt, Emily BS 2; Le Compte, Circe J.G. PhD 2; O'Malley, Denalee PhD 2,4; Stroup, Antoinette PhD 1,2; Paddock, Lisa E. PhD 1,2; Grumet, Sherry MS 2; Boyce, Tawny W. MS 5; Toppmeyer, Deborah L. MD 2,; McDougall, Jean A. PhD 6
doi : 10.1200/JCO.22.00751
Cancer genetic risk assessment (CGRA) is recommended for women with ovarian cancer or high-risk breast cancer, yet fewer than 30% receive recommended genetic services, with the lowest rates among underserved populations
Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial.
Vidrine, Jennifer I. PhD 1,2,3,; Sutton, Steven K. PhD 2,3,4; Wetter, David W. PhD, MS 5; Shih, Ya-Chen Tina PhD 6,; Ramondetta, Lois M. MD 7; Elting, Linda S. PhD, MPH 6; Walker, Joan L. MD 8,; Smith, Katie M. MD, MS 9; Frank-Pearce, Summer G. PhD 10,11,12; Li, Yisheng PhD 13,; Jones, Sarah R. BA 1; Kendzor, Darla E. PhD 10,11,14,; Simmons, Vani N. PhD 1,2,3; Vidrine, Damon J. DrPH 1,3,
doi : 10.1200/JCO.22.01228
Women who smoke and have a history of cervical intraepithelial neoplasia (CIN) or cervical cancer represent a vulnerable subgroup at elevated risk for recurrence, poorer cancer treatment outcomes, and decreased quality of life.
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa, Tadaaki MD, PhD 1,; Hasegawa, Kosei MD, PhD 2,; Matsumoto, Koji MD 3,; Mori, Masahiko MD, PhD 4; Hirashima, Yasuyuki MD, PhD 5,; Takehara, Kazuhiro MD, PhD 6,; Ariyoshi, Kazuya MD, PhD 7; Kato, Tomoyasu MD, PhD 8; Yagishita, Shigehiro MD, PhD 9,; Hamada, Akinobu PhD 9,; Kawasaki, Mamiko MS 10; Kawashima, Satoshi PhD 10; Tomatsuri, Sawako MS 10,; Nagasaka, Yukari BS 10; Yoshida, Hiroshi MD, PhD 11; Machida, Ryunosuke ME 12; Hirakawa, Akihiro PhD 13,; Nakamura, Kenichi MD, PhD 10,; Yonemori, Kan MD, PhD 1,,
doi : 10.1200/JCO.22.02558
To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) expressing HER2.
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer.
Tagliamento, Marco MD 1,; Gennari, Alessandra MD, PhD 2,; Lambertini, Matteo MD, PhD 1,3,; Salazar, Ramon MD, PhD 4,; Harbeck, Nadia MD, PhD 5,; Del Mastro, Lucia MD 1,3,; Aguilar-Company, Juan MD 6,7; Bower, Mark MD, PhD 8,; Sharkey, Rachel BSN 8; Dalla Pria, Alessia MD 8; Plaja, Andrea MD 9; Jackson, Amanda BSN 10; Handford, Jasmine MSc 11; Sita-Lumsden, Ailsa MD, PhD 12; Martinez-Vila, Clara MD 13; Matas, Marta MD 13; Miguel Rodriguez, Ana MD 13; Vincenzi, Bruno MD, PhD 14,; Tonini, Giuseppe MD, PhD 14,; Bertuzzi, Alexia MD 15,; Brunet, Joan MD, PhD 16,; Pedrazzoli, Paolo MD 17,18,; D'Avanzo, Francesca MD 2; Biello, Federica MD 2,; Sinclair, Alasdair MD 19; Lee, Alvin J.X. MD 19; Rossi, Sabrina MD 15,; Rizzo, Gianpiero MD 17; Mirallas, Oriol MD 6,; Pimentel, Isabel MD 6,; Iglesias, Maria MD 20,; Sanchez de Torre, Ana MD 21; Guida, Annalisa MD 22,; Berardi, Rossana MD, PhD 23,; Zambelli, Alberto MD, PhD 24,; Tondini, Carlo MD 24,; Filetti, Marco MD 25; Mazzoni, Francesca MD 26; Mukherjee, Uma MD, PhD 27; Diamantis, Nikolaos MD, PhD 27; Parisi, Alessandro MD 28; Aujayeb, Avinash MD 29; Prat, Aleix MD, PhD 30,31,; Libertini, Michela MD 32; Grisanti, Salvatore MD 33,; Rossi, Maura MD 34; Zoratto, Federica MD 35; Generali, Daniele MD, PhD 36,37,; Saura, Cristina MD, PhD 38,; Lyman, Gary H. MD, MPH 39,40,41,; Kuderer, Nicole M. MD 42,; Pinato, David J. MD, PhD 2,43,; Cortellini, Alessio MD, PhD 14,43,
doi : 10.1200/JCO.22.01667
Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Sallman, David A. MD 1,,; Al Malki, Monzr M. MD 2,; Asch, Adam S. MD 3,; Wang, Eunice S. MD 4,; Jurcic, Joseph G. MD 5,; Bradley, Terrence J. MD 6,; Flinn, Ian W. MD 7,; Pollyea, Daniel A. MD, MS 8,; Kambhampati, Suman MD 9; Tanaka, Tiffany N. MD 10,; Zeidner, Joshua F. MD 11,; Garcia-Manero, Guillermo MD 12,; Jeyakumar, Deepa MD 13,; Komrokji, Rami MD 1,; Lancet, Jeffrey MD 1,; Kantarjian, Hagop M. MD 12,; Gu, Lin MS 14,; Zhang, Yajia PhD 14,; Tan, Anderson PharmD, RPh 14,; Chao, Mark MD, PhD 14,; O'Hear, Carol MD, PhD 14,; Ramsingh, Giridharan MD 14,; Lal, Indu MD 14,; Vyas, Paresh MD, PhD 15,; Daver, Naval G. MD 12,
doi : 10.1200/JCO.22.01794
Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is synergistic with azacitidine, which increases expression of eat-me signals.
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta, Elisabetta PhD 1; Robin, Marie MD 2,; Bersanelli, Matteo PhD 3; Travaglino, Erica BSc 1; Meggendorfer, Manja PhD 4,; Zhao, Lin-Pierre MD 2; Caballero Berrocal, Juan Carlos MD 5,; Sala, Claudia PhD 6; Maggioni, Giulia MD 1; Bernardi, Massimo MD 7,; Di Grazia, Carmen MD 8; Vago, Luca MD 7; Rivoli, Giulia MD 8; Borin, Lorenza MD 9,; D'Amico, Saverio MEng 1; Tentori, Cristina Astrid MD 1; Ubezio, Marta MD 1; Campagna, Alessia MD 1; Russo, Antonio MD 1,; Mannina, Daniele MD 1; Lanino, Luca MD 1; Chiusolo, Patrizia MD 10,; Giaccone, Luisa MD 11,,12; Voso, Maria Teresa MD 13,; Riva, Marta MD 14; Oliva, Esther Natalie MD 15; Zampini, Matteo PhD 1; Riva, Elena PhD 1; Nibourel, Olivier PhD 16,; Bicchieri, Marilena PhD 1; Bolli, Niccolo' MD 17,18,; Rambaldi, Alessandro MD 19,20,; Passamonti, Francesco MD 21,22,; Savevski, Victor MEng 1; Santoro, Armando MD 1,3,; Germing, Ulrich MD 23,; Kordasti, Shahram MD 24,25,; Santini, Valeria MD 26,; Diez-Campelo, Maria MD 5,; Sanz, Guillermo MD 27,; Sole, Francesc PhD 28; Kern, Wolfgang MD 4,; Platzbecker, Uwe MD 29,; Ades, Lionel MD 2,; Fenaux, Pierre MD 2,; Haferlach, Torsten MD 4,; Castellani, Gastone PhD 6; Della Porta, Matteo Giovanni MD 1,3,
doi : 10.1200/JCO.22.01784
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M.
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto, Renata MD 1,; Sousa, Luana G. MD 1; Feng, Lei MS 2; Mott, Frank MD 1; Blumenschein, George MD 1,; Altan, Mehmet MD 1,; Bell, Diana MD 3; Bonini, Flavia MD 1; Li, Kaiyi MD 1; Marques-Piubelli, Mario L. MD 4; Dal Lago, Eduardo A. MD 5; Johnson, Jason J. MD 5,; Mitani, Yoshitsugu DDS, PhD 6; Godoy, Myrna MD 5,; Lee, Anna MD 7; Kupferman, Michael MD 8,; Hanna, Ehab MD 8; Glisson, Bonnie S. MD 1,; Elamin, Yasir MD 1,; El-Naggar, Adel MD, PhD 6
doi : 10.1200/JCO.22.02221
e conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
ASCO Ethical Guidance for the US Oncology Community Where Reproductive Health Care Is Limited by Law.
Spence, Rebecca A. JD, MPH 1,; Hinyard, Leslie J. PhD, MSW 2; Jagsi, Reshma MD, DPhil 3,; Jimenez, Rachel B. MD 4,; Lopez, Ana Maria MD, MPH 5; Chavez-MacGregor, Mariana MD, MSc 6; Spector-Bagdady, Kayte JD, MBE 7; Rosenberg, Abby R. MD, MS, MA 8
doi : 10.1200/JCO.23.00174
AB The decision in Dobbs v Jackson Women's Health Organization overturned federal protections for abortion rights, making way for states to enact abortion bans with or without exceptions for the health or life of the pregnant patient. Patient care across many areas of medicine including oncology continues to be affected.
Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma.
Yu, Guo PhD; Zhang, Na BM; Guan, Ai-Jia BM; Qiao, Yu-Wei BM; Li, Guo-Fu PhD
doi : 10.1200/JCO.23.00057
Reply to G. Yu et al.
Wu, Hao-Xiang; Pan, Yi-Qian; Wang, Zi-Xian; Wang, Feng
doi : 10.1200/JCO.23.00358
Erratum: Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.
doi : 10.1200/JCO.23.00633
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1
Singh, Navneet MD, DM 1,; Jaiyesimi, Ishmael A. DO, MS 2; Ismaila, Nofisat MD, MSc 3,; Leighl, Natasha B. MD 4,; Mamdani, Hirva MD 5,; Phillips, Tanyanika MD, MPH 6; Owen, Dwight H. MD, MS 7,
doi : 10.1200/JCO.23.00281
AB Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice.
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
Singh, Navneet MD, DM 1; Jaiyesimi, Ishmael A. DO, MS 2; Ismaila, Nofisat MD, MSc 3,,; Leighl, Natasha B. MD 4,; Mamdani, Hirva MD 5,; Phillips, Tanyanika MD, MPH 6; Owen, Dwight H. MD, MS 7,
doi : 10.1200/JCO.23.00282
AB Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice.
